Clinical Trial News and Research

RSS

Rockwell Medical first-quarter sales up 17.1%

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported first quarter 2010 results today.

5 May 2010

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring StemCells Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

5 May 2010

BioClinica reports service revenues of $14,746,000 for first-quarter 2010

BioClinica, Inc., a global provider of clinical trial management services, today announced its financial results for the first quarter ended March 31, 2010.

From Clario 5 May 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three London scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

Three Hamilton scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announced at BIO2010 in Chicago that its proposal to conduct a Phase I clinical trial on SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma, has been approved in the UK by the Gene Therapy Advisory Committee and by the Medicines and Healthcare products Regulatory Agency Medicines Division.

5 May 2010

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

An estimated 26.2 percent of Americans ages 18 and older - about one in four adults - suffer from a diagnosable mental disorder every year, which equates to approximately 57.7 million adults. Severe psychiatric illness affects a much smaller number of people - about 6 percent, or 1 in 17. Worldwide, an estimated 340 million people suffer from an episode of major depression every year.

5 May 2010

StemCells first-quarter total revenue up 307%

StemCells, Inc., a leading stem cell technology company with the dual focus of novel therapeutics and innovative research products, today reported financial results for the first quarter ended March 31, 2010 and recent business highlights.

5 May 2010

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Rates of colorectal cancer screening vary by race and ethnicity as well as method, according to data being presented at Digestive Disease Week- 2010. Scientists examine data on minority and older populations as well as utilization rates of virtual and optical colonoscopies to better understand adherence to recommended screening guidelines.

5 May 2010

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Particular parvoviruses normally infect rodents, but they are also infectious for human cells. However, they do not cause any disease symptoms in humans. Most importantly, these viruses have an astonishing property: They kill infected tumors cells without causing any damage to healthy tissue.

5 May 2010

High doses of antioxidant nutritional supplements may predispose cells to develop cancer

High doses of antioxidant nutritional supplements, such as vitamins C and E, can increase genetic abnormalities in cells, which may predispose supplement-takers to developing cancer, according to a new study from the Cedars-Sinai Heart Institute.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010

Latest version of Phase Forward CDC released

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the latest version of the Phase Forward Clinical Development Center, a centralized solution for integrating, managing and analyzing clinical information.

5 May 2010

Study: Flaxseed diet reduces ovarian cancer, increases survival rates

In the race to find answers about ovarian cancer, researchers now have something to cluck about. For five years, University of Illinois researchers have been using the chicken as a model to study this deadly disease and have recently discovered that a diet enriched with flaxseed decreases severity of ovarian cancer and increases survival in hens.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection. The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients requiring concomitant antibiotics, compared to vancomycin.

5 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx, Inc. today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc in March 2010.

4 May 2010

Clinical Trial News and Research

Rockwell Medical first-quarter sales up 17.1%

STEM reports net loss of $6,124,000 for first-quarter 2010: MicroStockProfit.com

BioClinica reports service revenues of $14,746,000 for first-quarter 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three Hamilton scientists receive cancer research grants from Canadian Cancer Society

UK GTAC, MHRA approve Scancell's Phase I clinical trial of SCIB1 DNA ImmunoBody vaccine

Ventral striatum plays important role in circuitry of reward-oriented behavior: Researchers

StemCells first-quarter total revenue up 307%

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Study: Parvovirus therapy offers complete regression of malignant brain tumors

High doses of antioxidant nutritional supplements may predispose cells to develop cancer

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Latest version of Phase Forward CDC released

Study: Flaxseed diet reduces ovarian cancer, increases survival rates

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Celldex reports net loss of $6.6 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer